Literature DB >> 7166913

Prognostic significance of lymphocyte proliferative responses to mitogens in gastric cancer patients.

T Toge, M Oride, E Yanagawa, S Hamamoto, H Kohno, K Nakanishi, T Hattori.   

Abstract

In 501 Japanese patients with gastric cancer, the relationships between preoperative lymphocyte proliferative (LP) responses to mitogens and prognosis of patients were evaluated. Peripheral blood lymphocytes were cultured in the presence of either autologous or allogeneic serum and their LP responses to phytohemagglutinin (PHA) and pokeweed mitogen were investigated. An apparent inverse relationship between LP responses and stage of the disease was found in LP responses to PHA in the presence of autologous serum. The survival rate of patients with higher responses was significantly greater than those with lower responses, when LP responses to PHA in the presence of autologous serum served as the criterion. Probabilities of staging which were computed on the basis of LP response to PHA affirmed the reciprocal relationship between LP responses and stage of the disease. From these results, it is concluded that evaluation of LP responses may be a valuable tool in the assessment of the clinical stage and in the prediction of prognosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7166913     DOI: 10.1007/bf02469832

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  10 in total

1.  Lymphocyte responsiveness to phytohemagglutinin (PHA) and serum inhibitory effect in patients with gastric cancer.

Authors:  T Toge; H Ikeda; N Senoo; M Niimoto; T Hattori
Journal:  Jpn J Surg       Date:  1976-12

2.  Thymus-dependent lymphocyte levels in bronchogenic carcinoma: correlations with histology, clinical stage, and clinical course after surgical treatment.

Authors:  A L Dellon; C Potvin; P B Chretien
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

3.  The peripheral lymphocyte count as an aid in the clinical staging of lung cancer.

Authors:  S P Aarons; W A Albano; R E Harris; C H Organ
Journal:  Ann Surg       Date:  1978-03       Impact factor: 12.969

4.  Lymphocyte responsiveness to phytohemagglutinin and its modification by serum inhibitor in breast cancer patients.

Authors:  T Toge; Y Nagusa; A Nakano; H Ikeda; T Hattori
Journal:  Gan       Date:  1979-04

5.  Cellular immune competence of breast cancer patients receiving radiotherapy.

Authors:  A B Cosimi; F H Brunstetter; W T Kemmerer; B N Miller
Journal:  Arch Surg       Date:  1973-10

6.  Correlation of preoperative lymphocyte reactivity with the clinical course of cancer patients.

Authors:  P B Chretien; W L Crowder; H R Gertner; W F Sample; W J Catalona
Journal:  Surg Gynecol Obstet       Date:  1973-03

7.  The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification.

Authors:  T Kajitani
Journal:  Jpn J Surg       Date:  1981-03

8.  Immunobiology of operable breast cancer: an assessment of biologic risk by immunoparameters.

Authors:  H J Wanebo; P P Rosen; T Thaler; J A Urban; H F Oettgen
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

9.  Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer.

Authors:  G B Cannon; J H Dean; R B Herberman; E Perlin; J Reid; C Miller; N P Lang
Journal:  Int J Cancer       Date:  1980-01-15       Impact factor: 7.396

10.  The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients to mitogens and alloantigens.

Authors:  J H Dean; R Connor; R B Herberman; J Silva; J L McCoy; R K Oldham
Journal:  Int J Cancer       Date:  1977-09-15       Impact factor: 7.396

  10 in total
  1 in total

Review 1.  New allogeneic hematopoietic stem cell transplantation method: hematopoietic stem cell transplantation plus thymus transplantation for intractable diseases.

Authors:  Naoki Hosaka
Journal:  Clin Dev Immunol       Date:  2013-05-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.